Alexandria Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Alexandria Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$7.54M	Buy	60,010 +758	+1%	+$97.6K	0.7%	51
2021 Q2	$8.02M	Buy	59,252 +1,052	+2%	+$138K	0.74%	49
2021 Q1	$7.89M	Sell	58,200 -859	-1%	-$129K	0.8%	42
2020 Q4	$8.31M	Buy	59,059 +11,036	+23%	+$1.41M	0.88%	32
2020 Q3	$5.34M	Buy	48,023 +7,499	+19%	+$841K	0.64%	52
2020 Q2	$4.54M	Buy	40,524 +27,764	+218%	+$2.73M	0.59%	60
2020 Q1	$988K	Buy	12,760 +1,084	+9%	+$96K	0.16%	126
2019 Q4	$1.11M	Buy	11,676 +2,171	+23%	+$188K	0.15%	131
2019 Q3	$725K	Buy	9,505 +4,350	+84%	+$362K	0.11%	148
2019 Q2	$452K	Buy	+5,155	New	+$440K	0.06%	190

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alexandria Capital's XBI Position: Q3 2021 in Review

Alexandria Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1.3% in Q3 2021, buying an estimated $97.6K and bringing the position to 60,010 shares worth $7.54M. The position accounts for 0.7% of the portfolio, ranked #51.

Alexandria Capital first reported a position in XBI in Q2 2019 and has held it in 10 quarters since. The position peaked at $8.31M in Q4 2020. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

Alexandria Capital held 60,010 shares of State Street SPDR S&P Biotech ETF worth $7.54M as of Q3 2021.
Alexandria Capital bought 758 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $97.6K.
State Street SPDR S&P Biotech ETF made up 0.7% of Alexandria Capital's portfolio in Q3 2021, its #51 holding.
Alexandria Capital first reported a position in State Street SPDR S&P Biotech ETF in Q2 2019 and has held it in 10 quarters since.
Alexandria Capital's State Street SPDR S&P Biotech ETF position peaked at $8.31M in Q4 2020.
635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.